Get the Stockscreener App
17.40
3.12%
-0.56
After Hours:
17.60
0.20
+1.15%
Sarepta Therapeutics Inc stock is traded at $17.40, with a volume of 1.57M.
It is down -3.12% in the last 24 hours and down -17.69% over the past month.
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
See More
Previous Close:
$17.96
Open:
$17.96
24h Volume:
1.57M
Relative Volume:
0.49
Market Cap:
$1.82B
Revenue:
$2.48B
Net Income/Loss:
$-57.96M
P/E Ratio:
-22.94
EPS:
-0.7585
Net Cash Flow:
$-453.97M
1W Performance:
+2.17%
1M Performance:
-17.69%
6M Performance:
-7.45%
1Y Performance:
-84.15%
1-Day Range:
$17.24
$18.09
1-Week Range:
$17.24
$18.69
52-Week Range:
$10.41
$111.20
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
Name
Sarepta Therapeutics Inc
Sector
Industry
Phone
617-274-4000
Address
215 FIRST STREET, CAMBRIDGE, MA
Compare SRPT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
17.40 | 1.88B | 2.48B | -57.96M | -453.97M | -0.7585 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Resumed | Barclays | Equal Weight |
| Dec-09-25 | Initiated | Wedbush | Outperform |
| Nov-05-25 | Upgrade | Mizuho | Neutral → Outperform |
| Sep-22-25 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jul-29-25 | Upgrade | Barclays | Underweight → Equal Weight |
| Jul-29-25 | Initiated | Bernstein | Mkt Perform |
| Jul-29-25 | Reiterated | H.C. Wainwright | Sell |
| Jul-29-25 | Upgrade | JP Morgan | Underweight → Neutral |
| Jul-29-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-28-25 | Downgrade | Barclays | Equal Weight → Underweight |
| Jul-25-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-24-25 | Initiated | Citigroup | Sell |
| Jul-23-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-22-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jul-21-25 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-21-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-21-25 | Downgrade | Mizuho | Outperform → Neutral |
| Jul-21-25 | Downgrade | Needham | Hold → Underperform |
| Jul-21-25 | Downgrade | UBS | Buy → Neutral |
| Jul-18-25 | Downgrade | Needham | Buy → Hold |
| Jun-20-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-18-25 | Downgrade | TD Cowen | Buy → Hold |
| Jun-17-25 | Initiated | Wolfe Research | Peer Perform |
| Jun-16-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jun-16-25 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-16-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jun-16-25 | Downgrade | H.C. Wainwright | Neutral → Sell |
| Jun-16-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-16-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jun-06-25 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| May-08-25 | Downgrade | Evercore ISI | Outperform → In-line |
| Apr-11-25 | Initiated | Wells Fargo | Overweight |
| Apr-02-25 | Upgrade | H.C. Wainwright | Sell → Neutral |
| Mar-31-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-11-25 | Initiated | Deutsche Bank | Hold |
| Nov-27-24 | Reiterated | Needham | Buy |
| Nov-25-24 | Initiated | H.C. Wainwright | Sell |
| Nov-07-24 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-21-24 | Initiated | Jefferies | Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Jul-29-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jun-26-24 | Downgrade | Citigroup | Buy → Neutral |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| May-28-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-14-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-31-24 | Initiated | BMO Capital Markets | Outperform |
| Dec-13-23 | Resumed | Citigroup | Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Nov-21-23 | Initiated | Wedbush | Outperform |
| Oct-31-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-31-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-23-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Apr-26-23 | Initiated | SMBC Nikko | Outperform |
| Apr-04-23 | Initiated | Citigroup | Buy |
| Mar-01-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-22-22 | Reiterated | BTIG Research | Buy |
| Dec-16-22 | Upgrade | UBS | Neutral → Buy |
| Apr-04-22 | Resumed | Cantor Fitzgerald | Overweight |
| Jan-05-22 | Reiterated | Needham | Buy |
| Dec-09-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-05-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-15-21 | Upgrade | Guggenheim | Neutral → Buy |
| Aug-05-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Neutral |
| Jan-12-21 | Downgrade | Citigroup | Buy → Neutral |
| Jan-11-21 | Downgrade | UBS | Buy → Neutral |
| Jan-08-21 | Downgrade | JP Morgan | Overweight → Underweight |
| Jan-08-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-08-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-11-20 | Initiated | Berenberg | Hold |
| Oct-28-20 | Initiated | UBS | Buy |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Aug-20-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-31-20 | Initiated | Mizuho | Buy |
| Nov-01-19 | Initiated | Guggenheim | Buy |
| Aug-21-19 | Reiterated | Needham | Buy |
| Jul-09-19 | Reiterated | Morgan Stanley | Overweight |
| Jul-01-19 | Reiterated | RBC Capital Mkts | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Mar-11-19 | Reiterated | Credit Suisse | Outperform |
| Oct-12-18 | Initiated | Bernstein | Outperform |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-26-18 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-14-18 | Resumed | BofA/Merrill | Buy |
| Sep-06-18 | Initiated | Credit Suisse | Outperform |
| Aug-01-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-21-18 | Reiterated | Robert W. Baird | Outperform |
| Jun-20-18 | Reiterated | Needham | Buy |
| Jun-19-18 | Reiterated | H.C. Wainwright | Buy |
View All
Sarepta Therapeutics Inc Stock (SRPT) Latest News
Has Sarepta Therapeutics (SRPT) Fallen Too Far After Its Sharp Multi‑Year Share Price Slide? - simplywall.st
Sarepta Therapeutics to announce fourth quarter and full-year 2025 financial results - marketscreener.com
Sarepta Therapeutics To Announce Fourth Quarter And Full-Year 2025 Financial Results - TradingView
Sarepta Therapeutics to Report Q4 and Full-Year 2025 Financial Results - Intellectia AI
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results - Business Wire
New York State Common Retirement Fund Has $703,000 Position in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
(SRPT) Risk Channels and Responsive Allocation - Stock Traders Daily
New Zealand OKs Phase 1 trial of Huntington’s therapy SRP-1005 - huntingtonsdiseasenews.com
Analysts Offer Insights on Healthcare Companies: Vir Biotechnology (VIR), M3 (OtherMTHRF) and Sarepta Therapeutics (SRPT) - The Globe and Mail
Global Gene Therapy and CRISPR Market Shows Billion Dollar Growth with Novartis Zolgensma 1.2 Billion Sarepta Elevidys 611 Million and Emerging CRISPR Collaborations 20 Million - Yahoo Finance
Following Sarepta Woes, Others Look To Unlock the Next Chapter in DMD Treatment - BioSpace
Analysts Offer Insights on Healthcare Companies: Veracyte (VCYT), Sarepta Therapeutics (SRPT) and Viridian Therapeutics (VRDN) - The Globe and Mail
Johnson Fistel, PLLP Begins Investigation on Behalf of - GlobeNewswire
Is Sarepta (SRPT) Quietly Redefining Its Rare Disease Strategy With a Huntington’s Trial Bet? - simplywall.st
Sarepta Saga Has ‘Gone on Too Long’ as Competitors Catch Up - BioSpace
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Average Rating of "Hold" by Brokerages - MarketBeat
Sarepta Therapeutics announces clinical trial application approval for SRP-1005 in Huntington's disease - marketscreener.com
Sarepta (SRPT) Receives Green Light for Huntington's Disease Tri - GuruFocus
Sarepta receives approval to start SRP-1005 trial in New Zealand - TipRanks
Sarepta gets New Zealand approval for Huntington’s disease trial By Investing.com - Investing.com India
Sarepta gets New Zealand approval for Huntington’s disease trial - Investing.com
Sarepta Therapeutics Announces Clinical Trial Application Approval For SRP-1005 In Huntington’s Disease - TradingView
Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington’s Disease - Sarepta Therapeutics
SAREPTA gets approval to test Huntington's disease treatment in humans - StreetInsider
Jobs Data: Will Sarepta Therapeutics Inc outperform its industry peersJuly 2025 Rallies & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
Assessing Sarepta Therapeutics (SRPT) Valuation After Positive Three Year EMBARK Data For Elevidys - Sahm
SRPT Plummets on Second Patient Death After DMD Gene Therapy Infusion - MSN
Sarepta Therapeutics, Inc. (SRPT) Stock Analysis: A Closer Look at Its 5.38% Potential Upside - DirectorsTalk Interviews
AAV Gene Therapy Market is Thriving Worldwide | Novartis - openPR.com
Sarepta’s Elevidys Data Reshapes Duchenne Risk Profile For Long-Term Investors - Sahm
Sarepta’s Elevidys Data Underscore Long Term Duchenne Therapy Durability - Yahoo Finance
Is Sarepta Therapeutics (SRPT) Pricing Reflect A 82% Share Price Slump And DCF Upside? - Yahoo Finance
Institutional Owners May Take Dramatic Actions as Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Recent 3.7% Drop Adds to One-year Losses - 富途牛牛
Y Intercept Hong Kong Ltd Lowers Position in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Sarepta Therapeutics Touts 3-Year EMBARK Data Showing ELEVIDYS Slows DMD Decline, No New Safety Flags - MarketBeat
(SRPT) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Commit To Purchase Sarepta Therapeutics At $15, Earn 22.2% Annualized Using Options - Nasdaq
How Sarepta’s Long-Term ELEVIDYS Duchenne Data At Sarepta Therapeutics (SRPT) Has Changed Its Investment Story - simplywall.st
Sarepta sells Arrowhead stock, activates $100M milestone payment - MSN
Sell Signal: Can Sarepta Therapeutics Inc. be recession proofTrade Risk Summary & Weekly Top Performers Watchlists - mfd.ru
Regenxbio Falls Most Ever After Tumor Found in Trial Participant - Bloomberg.com
Sarepta Therapeutics (NASDAQ:SRPT) Now Covered by Analysts at Barclays - MarketBeat
Roche Makes Obesity Splash, Moderna Cans Vaccine Trials, Sarepta’s New Data, More - BioSpace
SRPT Stock Up 8% on Positive Long-Term Data From Elevidys Study in DMD - The Globe and Mail
HC Wainwright Reiterates Sell Rating for Sarepta Therapeutics (NASDAQ:SRPT) - MarketBeat
Sarepta (SRPT): Analyst Reiterates Sell Rating Due to Data Conce - GuruFocus
Sarepta eyes Elevidys sales comeback with positive Phase III data - Yahoo Finance
Sarepta Therapeutics (SRPT): Analyst Reiterates Sell Rating Toda - GuruFocus
Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients - BioSpace
Sarepta Therapeutics (SRPT) upgraded to buy: What does it mean for the stock? - MSN
Sarepta Therapeutics Elevidys Data Highlights Durable Duchenne Benefits And Risks - Sahm
Sarepta Therapeutics Inc Stock (SRPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):